Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes.

Kneissl S, Zhou Q, Schwenkert M, Cosset FL, Verhoeyen E, Buchholz CJ.

PLoS One. 2013 Nov 11;8(11):e79047. doi: 10.1371/journal.pone.0079047. eCollection 2013.

2.

Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors.

Frecha C, Lévy C, Costa C, Nègre D, Amirache F, Buckland R, Russell SJ, Cosset FL, Verhoeyen E.

J Virol. 2011 Jun;85(12):5975-85. doi: 10.1128/JVI.00324-11. Epub 2011 Mar 30.

3.

Targeted cell entry of lentiviral vectors.

Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ.

Mol Ther. 2008 Aug;16(8):1427-36. doi: 10.1038/mt.2008.128. Epub 2008 Jun 24.

4.

Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors.

Frecha C, Costa C, Lévy C, Nègre D, Russell SJ, Maisner A, Salles G, Peng KW, Cosset FL, Verhoeyen E.

Blood. 2009 Oct 8;114(15):3173-80. doi: 10.1182/blood-2009-05-220798. Epub 2009 Aug 10.

5.

Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM.

Zhou Q, Schneider IC, Gallet M, Kneissl S, Buchholz CJ.

Virology. 2011 May 10;413(2):149-52. doi: 10.1016/j.virol.2011.02.010. Epub 2011 Apr 5.

6.

Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies.

Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaulies J, Buchholz CJ.

PLoS One. 2012;7(10):e46667. doi: 10.1371/journal.pone.0046667. Epub 2012 Oct 10.

7.

Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.

Uhlig KM, Schülke S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD.

J Virol. 2015 Sep;89(17):9044-60. doi: 10.1128/JVI.00844-15. Epub 2015 Jun 17.

8.

Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins.

Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, Buchholz CJ, Springfeld C.

Gene Ther. 2013 Jan;20(1):16-23. doi: 10.1038/gt.2011.209. Epub 2012 Jan 5.

PMID:
22218301
9.

Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins.

Frecha C, Costa C, Nègre D, Gauthier E, Russell SJ, Cosset FL, Verhoeyen E.

Blood. 2008 Dec 15;112(13):4843-52. doi: 10.1182/blood-2008-05-155945. Epub 2008 Sep 23.

10.

Measles virus glycoprotein-pseudotyped lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic modification of monocyte-derived dendritic cells.

Humbert JM, Frecha C, Amirache Bouafia F, N'Guyen TH, Boni S, Cosset FL, Verhoeyen E, Halary F.

J Virol. 2012 May;86(9):5192-203. doi: 10.1128/JVI.06283-11. Epub 2012 Feb 15.

11.

Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Frecha C, Lévy C, Cosset FL, Verhoeyen E.

Mol Ther. 2010 Oct;18(10):1748-57. doi: 10.1038/mt.2010.178. Epub 2010 Aug 24. Review.

12.

A scalable method to concentrate lentiviral vectors pseudotyped with measles virus glycoproteins.

Marino MP, Panigaj M, Ou W, Manirarora J, Wei CH, Reiser J.

Gene Ther. 2015 Mar;22(3):280-5. doi: 10.1038/gt.2014.125. Epub 2015 Jan 22.

PMID:
25608718
13.

Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells.

Lévy C, Amirache F, Costa C, Frecha C, Muller CP, Kweder H, Buckland R, Cosset FL, Verhoeyen E.

Mol Ther. 2012 Sep;20(9):1699-712. doi: 10.1038/mt.2012.96. Epub 2012 May 22.

14.

Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.

Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, Cattaneo R, Cichutek K, Buchholz CJ.

Gene Ther. 2009 May;16(5):700-5. doi: 10.1038/gt.2009.11. Epub 2009 Feb 12.

PMID:
19212424
15.

Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells.

Moreau T, Bardin F, Imbert J, Chabannon C, Tonnelle C.

Mol Ther. 2004 Jul;10(1):45-56.

16.

Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.

Grube M, Rezvani K, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA.

Clin Cancer Res. 2004 Feb 1;10(3):1047-56.

18.

Signaling through CD19, Fc receptors or transforming growth factor-beta: each inhibits the activation of resting human B cells differently.

Barrett TB, Shu GL, Draves KE, Pezzutto A, Clark EA.

Eur J Immunol. 1990 May;20(5):1053-9.

PMID:
1694130
19.

Targeting lentiviral vectors to specific cell types in vivo.

Yang L, Bailey L, Baltimore D, Wang P.

Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11479-84. Epub 2006 Jul 24.

20.

CD19 differentially regulates BCR signalling through the recruitment of PI3K.

Xu Y, Fairfax K, Light A, Huntington ND, Tarlinton DM.

Autoimmunity. 2014 Nov;47(7):430-7. doi: 10.3109/08916934.2014.921810. Epub 2014 Jun 23.

PMID:
24953501

Supplemental Content

Support Center